Lung cancer progress after first-line therapy: which treatment makes sense and which does not?
Symposium Chairs: F. Gamarra (Munich, Germany), K. Zarogoulidis (Thessaloniki, Greece)
Aims: The audience will learn that:
- second line chemotherapy offers a profound chance for improvement and prognosis for both nonsmall cell and small cell lung cancer patients
- the study data do not reflect the real circumstances of care as compared with studies on first-line regimens, especially for nonsmall cell lung cancer patients
- there has to be a different approach for patients with relapse concerning the balance between quality of life and tumour-specific treatment effects by chemotherapy.